PMID: 7544198May 1, 1995Paper

The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor

British Journal of Pharmacology
J W WatsonP L Andrews

Abstract

1. The selective NK1 receptor antagonist, CP-99,994, produced dose-related (0.1-1.0 mg kg-1, s.c.) inhibition of vomiting and retching in ferrets challenged with central (loperamide and apomorphine), peripheral (CuSO4) and mixed central and peripheral (ipecac, cisplatin) emetic stimuli. 2. Parallel studies with the enantiomer, CP-100,263 (1 mg kg-1, s.c.), which is > 1,000 fold less potent as a NK1 antagonist, indicated that it was without significant effect against CuSO4, loperamide, cisplatin and apomorphine-induced emesis. Against ipecac, it inhibited both retching and vomiting, expressing approximately 1/10th the potency of CP-99,994. 3. The 5-HT3 receptor antagonist, tropisetron (1 mg kg-1, s.c.) inhibited retching and vomiting to cisplatin and ipecac, but not CuSO4 or loperamide. 4. CP-99,994 (1 mg kg-1, i.v.) blocked retching induced by electrical stimulation of the ventral abdominal vagus without affecting the cardiovascular response, the apnoeic response to central vagal stimulation or the guarding and hypertensive response to stimulation of the greater splanchnic nerves. CP-99,994 (1 mg kg-1, i.v.) did not alter baseline cardiovascular and respiratory parameters and it failed to block the characteristic heart rate, bl...Continue Reading

References

Oct 1, 1991·Neuropharmacology·N M BarnesJ A Rudd
Jan 25, 1991·Science·R M SniderR W Spencer
Jan 1, 1991·Drug Design and Delivery·M B Tyers
Feb 1, 1990·Canadian Journal of Physiology and Pharmacology·P L AndrewsL Maskell
Nov 1, 1990·Journal of the Autonomic Nervous System·S MilanoA L Bianchi
Jul 1, 1989·Pharmacology, Biochemistry, and Behavior·J B Lucot, G H Crampton
Jan 1, 1989·British Journal of Clinical Pharmacology·P J BaconS E Smith
Nov 1, 1988·British Journal of Cancer·J BermudezG J Sanger
Sep 1, 1988·Trends in Pharmacological Sciences·P L AndrewsG J Sanger
Jul 1, 1987·Neuropharmacology·B CostallD Tattersall
Sep 1, 1987·International Journal of Radiation Oncology, Biology, Physics·R E CordtsK A Hardy
Jul 1, 1986·British Journal of Pharmacology·W D Miner, G J Sanger
Aug 1, 1986·Neuropharmacology·B CostallF D Tattersall
Jan 1, 1986·Progress in Brain Research·G J Dockray, K A Sharkey
Jun 1, 1983·Cellular and Molecular Neurobiology·D O CarpenterN Strominger
Mar 1, 1984·Behavioural Brain Research·D O CarpenterN Strominger
Jan 1, 1994·Brain Research Bulletin·N L StromingerD O Carpenter
Sep 1, 1994·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·P J Hesketh
Nov 30, 1993·European Journal of Pharmacology·F D TattersallR G Hill
Jan 1, 1993·Brain Research Bulletin·A P KnoxD O Carpenter

❮ Previous
Next ❯

Citations

May 25, 2005·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging
Sep 13, 2005·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Jarmo HietalaOlof Solin
Jun 3, 1996·European Journal of Pharmacology·S GonsalvesC Ashton
May 20, 1997·European Journal of Pharmacology·N M RupniakR J Hargreaves
Jan 7, 1999·European Journal of Pharmacology·M MinamiK Kisara
Aug 12, 1999·European Journal of Pharmacology·A Saria
Sep 6, 2002·Pharmacology, Biochemistry, and Behavior·Farideh A Javid, Robert J Naylor
Jan 1, 1997·Pharmacology & Therapeutics·P Holzer, U Holzer-Petsche
Dec 24, 1997·Journal of the Autonomic Nervous System·E R Partosoedarso, L A Blackshaw
Aug 8, 1998·Journal of the Autonomic Nervous System·J W ButcherJ F Paton
Apr 24, 1999·Neuroscience Letters·R SaitoH Kamiya
Nov 3, 2005·Nature Clinical Practice. Oncology·Thein H Oo, Paul J Hesketh
Jan 1, 1997·British Journal of Pharmacology·J B LucotJ W Watson
Jun 4, 1997·Journal of the National Cancer Institute·M G KrisP J Hesketh
Jul 11, 2000·Current Opinion in Oncology·H Bleiberg
Mar 1, 1996·British Journal of Pharmacology·J L MontastrucP Montastruc
Aug 24, 1999·Gut·J D WoodP L Andrews
Jan 28, 2005·The American Journal of Chinese Medicine·Sangeeta R MehendaleChun-Su Yuan
Mar 26, 2009·Magyar onkologia·Béla Pikó, Ali Bassam
Oct 13, 2000·Drugs·P Diemunsch, L Grélot
Oct 26, 2013·European Journal of Pharmacology·Howard S Smith, Andras Laufer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.